Hidradenitis suppurativa : Epidemiology, clinical presentation, and pathogenesis - 14/04/20

Doi : 10.1016/j.jaad.2019.08.090

Samantha R. Goldburg, BA ^a,^⁎ , Bruce E. Strober, MD, PhD ^b,^c, Michael J. Payette, MD, MBA ^a,^b,^d
^a University of Connecticut School of Medicine, Farmington, Connecticut
^b Central Connecticut Dermatology Research, Cromwell, Connecticut
^c Yale University, New Haven, Connecticut
^d Dermatology Department, Farmington, Connecticut

^∗Reprint requests: Samantha R. Goldburg, BA, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06032.University of Connecticut School of Medicine263 Farmington AveFarmingtonCT06032

Abstract

Hidradenitis suppurativa (HS) is an inflammatory disorder that is characterized by chronic deep-seated nodules, abscesses, fistulae, sinus tracts, and scars in the axilla, inguinal area, submammary folds, and perianal area. This disfiguring condition is accompanied by pain, embarrassment, and a significantly decreased quality of life. Although the mechanism of HS has not been entirely elucidated, lesion formation is believed to center around follicular hyperkeratosis within the pilosebaceous–apocrine unit. Recent research has provided new insight into the role of cytokines in the pathogenesis of HS, helping close some existing knowledge gaps in the development of this condition. The first article in this continuing medical education series reviews HS epidemiology, clinical presentation, and classification. We also provide an update on the most recent understanding of HS pathogenesis, including the central role of inflammatory cytokines and other contributing factors, such as genetics, hormones, and pathogenic microorganisms.

Le texte complet de cet article est disponible en PDF.

Key words : hidradenitis, hidradenitis suppurativa, IL-17, pathogenesis, TNF-α

Plan

Epidemiology

Quality of life

Presentation and clinical classification

Comorbidities and risk factors

Bacterial colonization

	Funding sources: None.
	Dr Strober serves as consultant for AbbVie, Almirall, Amgen, Arena, Aristea, Boehringer Ingelheim, Bristol-Myers-Squibb, Celgene, Dermavant, Dermira, Janssen, Leo, Eli Lilly, Kyowa Hakko Kirin, Meiji Seika Pharma, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologics, Regeneron, Sanofi-Genzyme. Dr Strober is also a speaker for AbbVie, Lilly, Janssen, Ortho Dermatologics. Dr Strober is also a scientific director for Corrona Psoriasis Registry. Dr Strober is also an investigator for Dermavant, AbbVie, Corrona Psoriasis Registry, Dermira. Dr Payette is a consultant for Abbvie Inc, Novartis, and Janssen Global Services.
	Date of release: May 2020
	Expiration date: May 2023